Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somapacitan versus Norditropin in children born small for gestational age with persistent short stature
2018-000232-10Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of somapacitan and somatropin in growth disorder (4 arms), sponsored by Novo Nordisk. Primary endpoint: Height velocity. Started Feb 2019; status: completed.
02
Drugs
somapacitansomatropin
03
Conditions
growth disorder
Beyond the preview
Go deeper on 2018-000232-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000232-10.